Nazmiye Turker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nazmiye Turker has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Tayfun Uçar
Department of Pediatric Cardiology, Faculty of Medicine, Ankara University, Ankara, Türkiye
2 shared publications - Ali Genco Gencay
Department of Pediatric Intensive Care, Istanbul Faculty of Medicine, Istanbul University, Millet Cad. Fındıkzade, Topkapı, Istanbul, 34093, Turkey
1 shared publication - Anar Gurbanov
Department of Pediatric Critical Care Medicine, Ankara University Faculty of Medicine, Ankara, Turkey
1 shared publication - Burak Balaban
Division of Pediatrics, Department of Pediatric Intensive Care, Ankara University Faculty of Medicine, Ankara, Turkey
1 shared publication - Edin Botan
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University School of Medicine, Ankara, Türkiye
1 shared publication - Emel Ünal
Department of Pediatric Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye
1 shared publication
Latest Publications
- 5 November 2026
- Published by Caleo in Turkish Archives of Pediatrics
Protective Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in the Treatment of Childhood Cancer
Objective: Anthracycline-based chemotherapy is used in 50%-60% of childhood cancers despite well-known cardiotoxicity. The authors evaluated dexrazoxane (DEX) as a cardioprotective agent in children receiving anthracyclines. Methods: The authors retrospectively analyzed 142 children aged 0-18 years treated for childhood cancer. The control group comprised 87 patients who received anthracycline alone (2009-2019) and the case group 55 patients who received DEX + anthracycline (2019-2022, after DEX was licensed in Türkiye). Cardiac dysfunction was defined as a left ventricular ejection fraction (LVEF) below 50%. Results: Baseline LVEF was comparable. Mean LVEF fell by 0.71 Å} 6.55 points with DEX vs. 6.44 Å} 9.76 in controls (Time Å~ Group interaction F(1,140) = 14.77, P < .001), and the difference persisted after adjustment for follow-up duration and treatment covariates (β = +4.60, 95% CI = 1.10-8.10, P = .010). Cardiac dysfunction developed in 11 of 87 controls (12.6%) and in none of the 55 DEX patients (P = .007; log-rank P = .040); this held in a 36-month landmark analysis (0 of 52 vs. 4 of 25, P = .009). Mortality was higher in controls (21.8% vs. 5.5%, P = .009) and in patients with cardiac dysfunction (54.5% vs. 17.1%, P = .012). Conclusion: Dexrazoxane attenuated the early decline in LVEF and reduced the incidence of anthracycline-induced cardiotoxicity, and this persisted after adjustment for the difference in follow-up duration. With a median DEX follow-up of only 22.8 months, these data support early cardioprotection; longer follow-up is needed to assess protection against late-onset cardiotoxicity.
- 5 November 2026
- Published by Caleo in Turkish Archives of Pediatrics
Protective Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in the Treatment of Childhood Cancer
Objective: Anthracycline-based chemotherapy is used in 50%-60% of childhood cancers despite well-known cardiotoxicity. The authors evaluated dexrazoxane (DEX) as a cardioprotective agent in children receiving anthracyclines. Methods: The authors retrospectively analyzed 142 children aged 0-18 years treated for childhood cancer. The control group comprised 87 patients who received anthracycline alone (2009-2019) and the case group 55 patients who received DEX + anthracycline (2019-2022, after DEX was licensed in Türkiye). Cardiac dysfunction was defined as a left ventricular ejection fraction (LVEF) below 50%. Results: Baseline LVEF was comparable. Mean LVEF fell by 0.71 Å} 6.55 points with DEX vs. 6.44 Å} 9.76 in controls (Time Å~ Group interaction F(1,140) = 14.77, P < .001), and the difference persisted after adjustment for follow-up duration and treatment covariates (β = +4.60, 95% CI = 1.10-8.10, P = .010). Cardiac dysfunction developed in 11 of 87 controls (12.6%) and in none of the 55 DEX patients (P = .007; log-rank P = .040); this held in a 36-month landmark analysis (0 of 52 vs. 4 of 25, P = .009). Mortality was higher in controls (21.8% vs. 5.5%, P = .009) and in patients with cardiac dysfunction (54.5% vs. 17.1%, P = .012). Conclusion: Dexrazoxane attenuated the early decline in LVEF and reduced the incidence of anthracycline-induced cardiotoxicity, and this persisted after adjustment for the difference in follow-up duration. With a median DEX follow-up of only 22.8 months, these data support early cardioprotection; longer follow-up is needed to assess protection against late-onset cardiotoxicity.
- 11 August 2021
- Published by Georg Thieme Verlag KG in Journal of Pediatric Intensive Care
- Vol. 12 (01) , 037-043
Multisystem Inflammatory Syndrome in Children Admitted to a Tertiary Pediatric Intensive Care Unit
Background Multisystem inflammatory syndrome in children (MIS-C) is characterized by persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, headaches, and mucocutaneous manifestations and it can cause circulatory dysfunction, resulting in hypotension, shock, and end-organ injury in the heart and other organs and possibly death. In this study, we aimed to analyze the clinical spectrum, treatment options and outcomes of children with MIS-C who were admitted to our pediatric intensive care (PICU). Materials and Methods Clinical and laboratory findings and treatment of the patients admitted to the PICU with MIS-C between April 2020 and January 2021 were recorded, and their outcomes were evaluated. Results Nineteen patients with a median age of 12.5 years (interquartile range (IQR): 5.8–14.0 years) were admitted. Eleven (57.8%) were males. The most frequent clinical and laboratory features were fever (100%), abdominal pain (94.7%), rash (63.1%), headache (68.4%), diarrhea (47.3%), seizure (10.5%), cardiac dysfunction (52.6%), acute kidney injury (26.3%), lymphopenia (84.2%), and thrombocytopenia (36.8%). However, 8 patients needed mechanical respiratory support, 11 patients needed inotropes, 2 patients needed plasma exchange, and 1 patient needed continuous renal replacement therapy. All patients received corticosteroids, 17 patients (89.2%) received intravenous immunoglobulin, 2 patients received anakinra, 10 patients received acetylsalicylic acid, and 6 patients received enoxaparin. Median PICU length of stay was 3 days (IQR: 2–5) and only one patient died. Conclusion In conclusion, MIS-C may present with a variety of clinical manifestations, and it can lead to life-threatening critical illness. Most children need intensive care and the response to immunomodulation is usually favorable.
- 11 August 2021
- Published by Georg Thieme Verlag KG in Journal of Pediatric Intensive Care
- Vol. 12 (01) , 037-043
Multisystem Inflammatory Syndrome in Children Admitted to a Tertiary Pediatric Intensive Care Unit
Background Multisystem inflammatory syndrome in children (MIS-C) is characterized by persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, headaches, and mucocutaneous manifestations and it can cause circulatory dysfunction, resulting in hypotension, shock, and end-organ injury in the heart and other organs and possibly death. In this study, we aimed to analyze the clinical spectrum, treatment options and outcomes of children with MIS-C who were admitted to our pediatric intensive care (PICU). Materials and Methods Clinical and laboratory findings and treatment of the patients admitted to the PICU with MIS-C between April 2020 and January 2021 were recorded, and their outcomes were evaluated. Results Nineteen patients with a median age of 12.5 years (interquartile range (IQR): 5.8–14.0 years) were admitted. Eleven (57.8%) were males. The most frequent clinical and laboratory features were fever (100%), abdominal pain (94.7%), rash (63.1%), headache (68.4%), diarrhea (47.3%), seizure (10.5%), cardiac dysfunction (52.6%), acute kidney injury (26.3%), lymphopenia (84.2%), and thrombocytopenia (36.8%). However, 8 patients needed mechanical respiratory support, 11 patients needed inotropes, 2 patients needed plasma exchange, and 1 patient needed continuous renal replacement therapy. All patients received corticosteroids, 17 patients (89.2%) received intravenous immunoglobulin, 2 patients received anakinra, 10 patients received acetylsalicylic acid, and 6 patients received enoxaparin. Median PICU length of stay was 3 days (IQR: 2–5) and only one patient died. Conclusion In conclusion, MIS-C may present with a variety of clinical manifestations, and it can lead to life-threatening critical illness. Most children need intensive care and the response to immunomodulation is usually favorable.